NEL Animal Cardiovascular Center Achieves World's First Surgical Correction of Complex VSD in Canine Patient
This veterinary milestone is highly significant, as it marks the first such case not only in Korea but also globally, with no previous reports of successful surgical treatment for complex VSDs.
The patient was diagnosed with a unique form of VSD—a single, continuous defect extending from the perimembranous to the subarterial region (Perimembranous VSD extending into subarterial region). Given that there had been no prior successful surgical cases even for typical VSDs in veterinary medicine, this breakthrough greatly expands the possibilities for surgical treatment of congenital heart disease in Korea's veterinary cardiac surgery field.
Over the past year, NEL's cardiac surgery team has gained experience through more than 50 open-heart surgeries using cardiopulmonary bypass. Based on this expertise, the team developed a thorough surgical plan. During the procedure, the complex VSD involving both membranous and subarterial regions was confirmed. The team performed incisions in the right atrium and pulmonary artery, successfully closing the defect with a bovine pericardial patch.
Immediately after surgery, the left-to-right shunt was completely resolved, and the risk of progressive regurgitation due to aortic valve prolapse was eliminated. The patient's cardiac function recovered to near-normal levels, and the long-term prognosis is considered highly favorable.
Subarterial VSDs are particularly dangerous due to the risk of aortic valve prolapse and severe regurgitation, making early surgical intervention crucial. The success of this surgery offers new hope for animals with congenital heart defects, demonstrating the potential for a surgical cure.
Dr. Tae-Heum Um, Director of NEL Animal Cardiovascular Center, stated,
"Although this was a complex defect, thorough discussion and preparation among our medical team led to a successful outcome. We will continue our efforts so that more animals with congenital heart disease can lead healthy and normal lives."
NEL Animal Cardiovascular Center is preparing an academic analysis and official report on this case, and sincerely hopes that this achievement contributes to the advancement of veterinary cardiac surgery not only in Korea, but also across Asia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618427466/en/
Contacts
NEL Animal Cardiovascular CenterYoon il-yong+82-31-421-7579heart@thenel.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
How Myeloma Plays Hide and Seek With CAR T Cells
TOPLINE: G protein-coupled receptor, class C, group 5, member D (GPRC5D) loss after chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) occurs through biallelic genetic inactivation and hypermethylation-driven epigenetic silencing. Among 10 patients who relapsed, eight showed GPRC5D loss, while two had mixed expression. METHODOLOGY: Researchers conducted whole-genome sequencing (WGS) and whole-genome bisulfite sequencing (WGBS) analysis on MM samples from 10 patients who relapsed after GPRC5D CAR T-cell therapy. Analysis included CD138+ MM cells isolated from bone marrow samples with purity exceeding 80%, with tumor samples sequenced at 100× coverage and matched normal samples at 30× coverage. Investigators performed targeted bisulfite sequencing to evaluate methylation status of GPRC5D regulatory regions across seven MM cell lines, with library construction and sequencing conducted by specialized institutes. Patient characteristics included median age of 57.5 years (range, 44-66 years), equal gender distribution, and 90% having high-risk cytogenetic abnormalities. TAKEAWAY: Genetic alterations were identified in three cases: one with homozygous deletion in GPRC5D gene, another with biallelic loss in regulatory regions, and a third with homozygous deletions in both TNFRSF17 and GPRC5D after sequential anti-B-cell maturation antigen and anti-GPRC5D CAR T-cell therapies. Multiple hypermethylation sites were present in transcriptional regulatory elements of GPRC5D gene in five posttreatment MM samples, with no genetic changes detected at GPRC5D locus in seven cases. GPRC5D expression showed inverse correlation with methylation levels in regulatory regions of MM cell lines, with azacitidine treatment inducing GPRC5D messenger RNA and protein expression in hypermethylated MM cell lines. All 10 patients achieved complete response or better as best response with median time to best response of 2.5 months (range, 0.5-15.3 months), though median time to disease progression was 15.9 months (range, 3.0-26.5 months). IN PRACTICE: 'Our findings highlight that biallelic genetic inactivation and hypermethylation-driven epigenetic silencing are key mechanisms contributing to GPRC5D loss and treatment resistance,' wrote the authors of the study. SOURCE: The study was led by Mingshan Niu, Blood Diseases Institute, Xuzhou Medical University in Xuzhou, China. It was published online in Blood. LIMITATIONS: According to the authors, the structural variant deletions on chromosomes may be missed by 100× WGS in patients with a clone size less than 20%. The limit of detection for quantitative polymerase chain reaction ranged from 16 to 50 copies per reaction, indicating sensitivity limitations of these detection methods. Additionally, genetic alterations in the GPRC5D locus could either be acquired after CAR T-cell therapy or selected from preexisting clones, necessitating more sensitive detection methods for dynamic monitoring. DISCLOSURES: The research received support from the National Natural Science Foundation of China (82270181) and the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (21KJA320005). The authors reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
3 hours ago
- Yahoo
China is catching up to the US in brain tech, rivaling firms like Elon Musk's Neuralink
'I want to eat' popped up in Chinese characters on a computer at a public hospital in central Beijing. The words were formed from the thoughts of a 67-year-old woman with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, who is unable to speak. The demonstration, captured on video in March by Beijing Radio and Television Station, was part of a clinical trial involving five patients implanted with a coin-sized chip called Beinao-1, a wireless so-called brain computer interface (BCI) – a technology led by scientists in the US, but in which experts say China is quickly catching up. Luo Minmin, director of the Chinese Institute for Brain Research (CIBR) and the chief scientist behind the trial, said there was a 'very strong' need for BCI technology, saying they had been 'overwhelmed' by requests from potential patients. 'The patients were saying that this feels so great, like they can gain or regain the control of (their) muscles,' he told CNN in May during a rare interview at his lab, located an hour's drive away from Beijing Xuanwu Hospital, where the trial took place. Luo said the technology was showing 'high accuracy' in decoding signals from the brains of patients and translating the signals into text speech or machine movements. His team is planning to speed up human trials by implanting chips into 50 to 100 more patients over the next year. 'We are hoping that we can move this process faster,' he said. 'If it's proven to be safe and effective … it can be used clinically across the world.' As of May, Beinao-1 says a total of five patients, the same number as Elon Musk's Neuralink, has its implants. Another US company Synchron, whose investors include Jeff Bezos and Bill Gates, has undergone trials with 10 patients, six in the United States and four in Australia. Maximilian Riesenhuber, a professor of neuroscience at Georgetown University who was not involved in the Beinao trials, told CNN that despite starting later than the US, China is making advances. 'China has definitely shown the ability to not just catch up, but also then be competitive, and now actually to start, also to drive the field in some areas,' he said. 'Excitingly, there's a lot of research activities in both countries, because they've realized the potential in BCI.' According to Precedence Research, a market research firm, the market for brain technology was worth about $2.6 billion last year and is expected to rise to $12.4 billion by 2034. But for both China and the US, this technology is about much more than cash. Chinese leader Xi Jinping has long aimed to turn his country into a science and economic powerhouse. In March, he wrote in state-owned media that the tech industry had become the 'forefront' and 'main battlefield' of global competition. His ambitions have sparked concern in the US, resulting in an ongoing tech war, particularly in the semiconductor industry. A different approach CIBR was jointly founded by the Beijing municipal government and several local universities in 2018, about two years after Elon Musk founded Neuralink near San Francisco. In 2023, CIBR incubated a private company named NeuCyber NeuroTech to focus on brain tech products such as Beinao-1. Luo, who is also the startup's chief scientist, gave CNN rare access to the institute in May. For years, he said, the ALS patient, who is in her 60s, was unable to express herself. 'She's awake, she knows what she wants but she could not speak out,' said the scientist, who got his PhD in neuroscience from the University of Pennsylvania and spent nearly a decade in the US. 'Following the implantation, she can now speak simple sentences quite accurately via the system.' All BCI researchers must address the balance between risk and effectiveness. Riensenhuber said most American firms use the more invasive method to place chips inside the dura mater, an outer layer of tissue that covers and protects the brain and spinal cord, in order to capture better signal. But these methods require riskier surgeries. 'It is interesting to see that NeuCyber is apparently able to get enough information even through the dura to allow the decoding of specific words,' he said. The test on the ALS patient, which began in March, marked the Beinao-1 chip's third trial in humans. Those trials made up what the developers described in a press release as 'the world's first batch of semi-invasive implantation of wireless BCI in human brains.' As of May, two more trials have been conducted, for a total of five. Clear ambition Amid rising geopolitical tensions, comparisons between US and Chinese tech breakthroughs are common. Brain computer interface technology first started in the 1970s in the US. Decades later, the Obama Administration launched its 'Brain Initiative' in 2013, investing more than $3 billion to fund over a thousand neuroscience technology projects since, according to the National Institute of Health. Synchron, based in New York, was the first firm to start human trials in July 2021. Three years later, a new BCI system developed at UC Davis Health translated the brain signals of an ALS patient into speech, achieving an accuracy of 97% – the most accurate system of its kind, the university said in a statement. The same year, Musk's company completed its first human trial, enabling the participant to control a computer mouse with a brain implant. China got its start in brain tech only in the 1990s, but it's advancing fast. In 2014, Chinese scientists introduced the idea of a national project on brain tech to match similar efforts in the US and Europe, according to the Ministry of Science and Technology. Two years later, brain tech was mentioned in the country's five-year plan, which outlines China's national priorities and goals. 'Brain science is new in China,' said Lily Lin, a former research assistant at one of China's top neuroscience research units from 2021 to 2023. 'So, it started a bit late, but its speed of development has been faster than other countries. And the country has given a lot of funding to many scientific research units, and this funding is increasing every year.' Last year, the government issued its first ethical guidelines for research in this area. At the local level, municipal governments in Beijing, Shanghai and other major cities have also offered support for brain technology companies from research and clinical trials to commercialization. Riesenhuber and other researchers from Georgetown University published research on China's BCI development in 2024, stating that efforts from Chinese researchers were 'comparable in sophistication' to those in the US and the United Kingdom. 'We found China's non-invasive BCI research to be comparable with that of other scientifically advanced nations and to be working to overcome obstacles to greater fidelity, throughput, and wider use,' according to the issue brief. 'China's invasive BCI research, while historically behind its non-invasive efforts, has picked up the pace and is approaching global standards of sophistication.' Luo, who has worked in both countries, says the US is the 'front-runner' in both invasive and non-invasive brain tech. But, comparing Beinao-1 and Neuralink is like looking at 'apples and oranges,' he added. The two systems differ not only in implant location but also in the type of brain signals recorded, as well as the method of data transmission. The Chinese chip records a wider range of brain areas, with lower precision for each neuron. 'All in all, I don't think these two products are in a competitive or exclusive relationship,' Luo added. 'The jury is still out, and we don't know yet which route will ultimately benefit patients better.' CNN's Joyce Jiang contributed to this report.
Yahoo
4 hours ago
- Yahoo
Taiwan plans AI projects to boost economy by $510 billion
TAIPEI (Reuters) -Taiwan plans to launch its "Ten Major AI Infrastructure Projects" initiative, aimed at generating more than T$15 trillion ($510 billion) in economic value by 2040 as it strives to become a global leader in artificial intelligence. Premier Cho Jung-tai said in a Facebook post late on Tuesday that Taiwan aims to leverage its information and communications technology (ICT) sector and world-leading semiconductor manufacturing capabilities to become a global AI influencer and a "smart technology island." Under the initiative, Taiwan has identified three core technologies as strategic priorities: silicon photonics, quantum technology and AI robotics. Silicon photonics is a technology that Taiwan's TSMC, the world's largest contract chipmaker, and many other firms in the industry are actively developing. The government aims to position Taiwan as a global leader in silicon photonics by aligning the sector with future AI development needs. Taiwan also hopes to become a key hub for AI robotics by tapping its hardware and ICT supply chains. Industry groups, including one led by Foxconn Chairman Young Liu, have backed the move with the formation of the Taiwan AI Robotics Industry Grand Alliance on Tuesday to support the local development of AI robotics and related ecosystems. Taiwan also plans to establish a quantum technology industry chain. The 10 projects also include the development of sovereign AI - ability to build and control domestic AI technologies - and computing infrastructure, efforts to balance AI development across different regions of the island, and the introduction of AI across a wide range of industries. The government also calls for expanding investment in AI innovation, with more than T$100 billion ($3.08 billion) in venture capital funding, as it seeks to become a global hub for AI talent and investment. The initiative targets the creation of 500,000 jobs and the establishment of three international-level research laboratories.
